CADTH conducted a Health Technology Review on remdesivir — an antiviral drug currently being used to treat COVID-19. Remdesivir was approved in Canada on July 27, 2020 to treat adults and adolescents with severe symptoms of COVID-19 who have pneumonia and require extra oxygen. Five randomized controlled trials were identified and included in the review.

Link to Report

Remdesivir: Evidence Review and Appraisal (updated February 19, 2021)


Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.